Document is current
Any future updates will be listed below
-
Authors
Fountzilas, Elena
Tsimberidou, Apostolia M.
Vo, Henry Hiep
Kurzrock, Razelle https://orcid.org/0000-0003-4110-1214
-
Funding
Funding for this research was provided by:
National Institutes of Health/National Cancer Institute (P30 CA016672 (The University of Texas MD Anderson Cancer Center))
Supported in part by donor funds from Jamie’s Hope, Mr. and Mrs. Zane W. Arrott, and Mr. and Mrs. Steven McKenzie for Dr. Tsimberidou’s Personalized Medicine Program
- License Information
-
More Information
Article History
Received: 29 June 2021
Accepted: 9 August 2022
First Online: 31 August 2022
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Elena Fountzilas has the following financial relationships to disclose: Travel grants: Merck, Pfizer, and K.A.M Oncology/Hematology; Speaker fees: Roche, Leo, Pfizer; Stock ownership: Deciphera Pharmaceuticals, Inc.Dr. Apostolia-Maria Tsimberidou has the following financial relationships to disclose: Research Funding (Institution): OBI Pharma, Parker Institute for Cancer Immunotherapy, Immatics, Tvardi Therapeutics, Tempus, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, Agenus and Novocure. Consulting or Advisory Role: Vincerx, Diaccurate.Dr. Razelle Kurzrock has the following financial relationships to disclose: Research Funding (Institution): Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Biologic Dynamics, Boehringer Ingelheim, Medimmune, and Guardant. Consulting role: X-Biotech, Loxo, Biologic Dynamics, Turning Point, TD2, Bicara, and Actuate Therapeutics. Speaker fees: Roche. Ownership interest: IDbyDNA and CureMatch, Inc. Board member: CureMatch and CureMetrix.Dr. Henry Hiep Vo reports no relevant conflicts of interest.
